Dennis J. Montoya

Dennis J. Montoya

Auto-generated profile, based on publicly available information

Dennis J. Montoya

The Health Equity Leadership, Science, and Community Research Laboratory, Genome Center, University of California, Davis, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in GigaScience
Verified
Journal Article
Open access
PDF file
BNBrian B Nadel
Brian B Nadel
DLDavid Lopez
David Lopez
DMDennis J Montoya
Dennis J Montoya
FMFeiyang Ma
Feiyang Ma
HWHannah Waddel
Hannah Waddel
MPMatteo Pellegrini
Matteo Pellegrini
Background: The cell type composition of heterogeneous tissue samples can be a critical variable in both clinical and laboratory settings. However, current experimental methods of cell type quantification (e.g., cell flow cytometry) are costly, time consuming and have potential to introduce bias. Computational approaches that use expression data to infer cell type abundance offer an alternative solution. While these methods have gained popularity, most fail to produce accurate predictions for the full range of platforms currently used by researchers or for the wide variety of tissue types often studied. Results: We present the Gene Expression Deconvolution Interactive Tool (GEDIT), a flexible tool that utilizes gene expression data to accurately predict cell type abundances. Using both simulated and experimental data, we extensively evaluate the performance of GEDIT and demonstrate that it returns robust results under a wide variety of conditions. These conditions include multiple platforms (microarray and RNA-seq), tissue types (blood and stromal), and species (human and mouse). Finally, we provide reference data from 8 sources spanning a broad range of stromal and hematopoietic types in both human and mouse. GEDIT also accepts user-submitted reference data, thus allowing the estimation of any cell type or subtype, provided that reference data are available. Conclusions: GEDIT is a powerful method for evaluating the cell type composition of tissue samples and provides excellent accuracy and versatility compared to similar tools. The reference database provided here also allows users to obtain estimates for a wide variety of tissue samples without having to provide their own data.

8 February 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Cristabelle De SouzaCristabelle De Souza
Cristabelle De Souza
JMJill Madden
Jill Madden
DKDevin C Koestler
Devin C Koestler
DMDennis Minn
Dennis Minn
DMDennis J Montoya
Dennis J Montoya
JCJeremy Chien
Jeremy Chien
TP53 mutations occur in more than 50% of cancers. We sought to determine the effect of the intragenic P72R single nucleotide polymorphism (SNP; rs1042522) on the oncogenic properties of mutant p53. P72R allelic selection in tumors was determined from genotype calls and a Gaussian distributed mixture model. The SNP effect on mutant p53 was determined in p53-negative cancer cell lines. RNA-sequencing, chromatin immunoprecipitation, and survival analysis were performed to describe the SNP effect. All statistical tests were 2-sided. Among 409 patients with germline heterozygous P72R SNP who harbored somatic mutations in TP53, we observed a selection bias against missense TP53 mutants encoding the P72 SNP (P = 1.64 x 10-13). Exogenously expressed hotspot p53 mutants with the P72 SNP were negatively selected in cancer cells. Gene expression analyses showed the enrichment of p53 pathway genes and inflammatory genes in cancer cells transduced with mutants encoding P72 SNP. Immune gene signature is enriched in patients harboring missense TP53 mutations with homozygous P72 SNP. These patients have improved overall survival as compared with those with the R72 SNP (P = .04). This is the largest study demonstrating a selection against the P72 SNP. Missense p53 mutants with the P72 SNP retain partial wild-type tumor-suppressive functions, which may explain the selection bias against P72 SNP across cancer types. Ovarian cancer patients with the P72 SNP have a better prognosis than with the R72 SNP. Our study describes a previously unknown role through which the rs1042522 SNP modifies tumor suppressor activities of mutant p53 in patients.

9 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YCYu-Ling Chang
Yu-Ling Chang
MRMaura Rossetti
Maura Rossetti
DGDavid W. Gjertson
David W. Gjertson
LRLiudmilla Rubbi
Liudmilla Rubbi
MTMichael Thompson
Michael Thompson
YZYing Zheng
Ying Zheng
Significance: Up to 30% of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections fail to resolve despite appropriate therapy. Such infections are persistent and life threatening. Because persistent MRSA isolates are susceptible to antibiotics in vitro, unique interactions among the pathogen, patient, and antibiotic occur in the body that lead to persistent outcomes. To study host factors involved in persistence, we used state-of-the-art methods to explore how genes are modified by methylation in patients who experience persistent vs. resolving MRSA bacteremia. Findings established distinct methylation patterns in these patients, including differential methylation signatures associated with important immune system and related genes. These results may enable approaches to identify and treat patients prone to persistent infection to improve therapeutic outcomes and save lives.

21 March 2022 in Epigenetics
Verified
Journal Article
Closed access
Marco MorselliMarco Morselli
Marco Morselli
CFColin Farrell
Colin Farrell
DMDennis Montoya
Dennis Montoya
TGTarık Gören
Tarık Gören
RSRamazan Sabirli
Ramazan Sabirli
MPMatteo Pellegrini
Matteo Pellegrini
Immune cell-type composition changes with age, potentially weakening the response to infectious diseases. Profiling epigenetics marks of immune cells can help us understand the relationship with disease severity. We therefore leveraged a targeted DNA methylation method to study the differences in a cohort of pneumonia patients (both COVID-19 positive and negative) and unaffected individuals from peripheral blood. This approach allowed us to predict the pneumonia diagnosis with high accuracy (AUC = 0.92), and the PCR positivity to the SARS-CoV-2 viral genome with moderate, albeit lower, accuracy (AUC = 0.77). We were also able to predict the severity of pneumonia (PORT score) with an R2 = 0.69. By estimating immune cellular frequency from DNA methylation data, patients under the age of 65 positive to the SARS-CoV-2 genome (as revealed by PCR) showed an increase in T cells, and specifically in CD8+ cells, compared to the negative control group. Conversely, we observed a decreased frequency of neutrophils in the positive compared to the negative group. No significant difference was found in patients over the age of 65. The results suggest that this DNA methylation-based approach can be used as a cost-effective and clinically useful biomarker platform for predicting pneumonias and their severity.

29 May 2025 in EBioMedicine
Verified
Journal Article
Open access
JGJoana Guerra
Joana Guerra
AEAna P Estrada-Florez
Ana P Estrada-Florez
PLPaul C Lott
Paul C Lott
CPCarla Pinto
Carla Pinto
MPManuela Pinheiro
Manuela Pinheiro
HGHispanic Gastric Cancer Genetics Collaborative Group
Hispanic Gastric Cancer Genetics Collaborative Group
Approximately 10% of cases with gastric cancer (GC) exhibit familial clustering, however, only 1-3% of cases can be explained by two known hereditary syndromes: Hereditary Diffuse Gastric Cancer (HDGC) caused by CDH1 and CTNNA1 pathogenic germline variants; and Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), caused by germline variants in APC 1B promoter. Familial intestinal gastric cancer (FIGC) has been defined clinically, but it remains mostly genetically unexplained. Likewise, the heritability of mixed histology GC remains to be known. We aimed to estimate the frequency of known cancer predisposition gene variants in GC cases with and without a cancer family history, diverse histological subtypes, and varied age of onset. We evaluated the contribution of pathogenic or likely pathogenic (P/LP) variants in well-established moderate-to-high penetrance multi-organ cancer predisposition genes for GC risk in a large international multi-centre retrospective cohort study involving 750 patients with GC of early-onset or family history of cancer, either by panel sequencing or whole exome sequencing (WES). Panel sequencing was conducted on 328 cases, while WES was performed on the remaining 422. Tumour sequence analyses were performed on samples from 15 patients with P/LP variants. Mutations identified in five index cases were also tested in their relatives. We identified 45 patients (6%) with P/LP variants in: ATM (17 cases), BRCA2 (10 cases), MLH1 (five cases), TP53 (three cases), BRCA1, PALB2, RAD51D, and CHEK2 (two patients each), and RAD51C and PMS2 (one case each), all of which were mutually exclusive. The P/LP variant prevalence was higher in intestinal (9.8%) than in diffuse (4.3%) or mixed GC (4.5%) (p-value = 0.023), without difference per mutated gene by histological subtypes. Only 16 of the 45 patients who carried P/LP variants fulfilled the National Comprehensive Cancer Network genetic testing criteria of at least one cancer predisposition syndrome. Our findings indicate that a broader panel of cancer predisposition genes, beyond CDH1 and CTNNA1, should be included in gene panels to investigate germline variants in patients with GC. This would be especially beneficial when there is a family history of cancer, irrespective of histology subtype, as it would increase the chance of identifying patients who could benefit from risk reduction, targeted treatment, and surveillance of other cancer types. National Cancer Institute of the National Institutes of Health, USA; Universidad del Tolima, Colombia; MINCIENCIAS, Colombia; L'OREAL-UNESCO-ICETEX-COLCIENCIAS, Colombia; Instituto Nacional de Cancerología, Colombia; American Association for Cancer Research, USA; ANID Ministerio de Ciencia, Chile; Fondecyt, Chile; CONICYT/ANID FONDAP, Chile; Instituto Mexicano del Seguro Social and Consejo Nacional de Ciencia y Tecnología, México; IPO Porto, Portugal; Liga Portuguesa Contra o Cancro, Portugal; Fundacao para a Ciencia e Tecnologia, Portugal; The Auburn Community Cancer Endowed Chair in Basic Research, USA; The Heart, BrEast, and BrAin HeaLth Equity Research (HEAL HER) program, a program made possible by residual class settlement funds in the matter of April Krueger v. Wyeth, Inc., Case No. 03-cv-2496 (US District Court, SD of Calif.), USA.

7 August 2019 in bioRxiv
Verified
Preprint
Open access
BNBrian B. Nadel
Brian B. Nadel
DLDavid Lopez
David Lopez
DMDennis J. Montoya
Dennis J. Montoya
FMFeiyang Ma
Feiyang Ma
HWHannah Waddel
Hannah Waddel
MPMatteo Pellegrini
Matteo Pellegrini
The cell type composition of heterogeneous tissue samples can be a critical variable in both clinical and laboratory settings. However, current experimental methods of cell type quantification (e.g. cell flow cytometry) are costly, time consuming, and can introduce bias. Computational approaches that infer cell type abundance from expression data offer an alternate solution. While these methods have gained popularity, most are limited to predicting hematopoietic cell types and do not produce accurate predictions for stromal cell types. Many of these methods are also limited to particular platforms, whether RNA-seq or specific microarrays. We present the Gene Expression Deconvolution Interactive Tool (GEDIT), a tool that overcomes these limitations, compares favorably with existing methods, and provides superior versatility. Using both simulated and experimental data, we extensively evaluate the performance of GEDIT and demonstrate that it returns robust results under a wide variety of conditions. These conditions include a variety of platforms (microarray and RNA-seq), tissue types (blood and stromal), and species (human and mouse). Finally, we provide reference data from eight sources spanning a wide variety of stromal and hematopoietic types in both human and mouse. This reference database allows the user to obtain estimates for a wide variety of tissue samples without having to provide their own data. GEDIT also accepts user submitted reference data, thus allowing the estimation of any cell type or subtype, provided that reference data is available. Author Summary: The Gene Expression Deconvolution Interactive Tool (GEDIT) is a robust and accurate tool that uses gene expression data to estimate cell type abundances. Extensive testing on a variety of tissue types and technological platforms demonstrates that GEDIT provides greater versatility than other cell type deconvolution tools. GEDIT utilizes reference data describing the expression profile of purified cell types, and we provide in the software package a library of reference matrices from various sources. GEDIT is also flexible and allows the user to supply custom reference matrices. A GUI interface for GEDIT is available at http://webtools.mcdb.ucla.edu/ , and source code and reference matrices are available at https://github.com/BNadel/GEDIT .